Physician profile
Sarah A Werner
NPI 1144459090
$1,936.60
in general payments reported to CMS, 2019-2025
21 companies · $396 in 2025
The $396 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.96 · 2020: $35.95 · 2021: $132 · 2022: $371 · 2023: $475 · 2024: $442 · 2025: $396.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,313.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,312.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $488.38 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $231.20 | 2019-2025 | |
| Lilly USA, LLC | $199.83 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $196.46 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $110.33 | 2023-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $108.44 | 2019-2025 | Farxiga |
| Exact Sciences Corporation | $83.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $69.00 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Biogen, INC. | $64.48 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $61.73 | 2022 | |
| Amgen INC. | $53.80 | 2021-2023 | Otezla, Repatha |
| E.R. Squibb & Sons, L.L.C. | $49.87 | 2022-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.82 | 2022 | |
| Cranial Technologies, INC | $34.67 | 2023-2024 | Doc Band |
| Shield Therapeutics INC | $34.32 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $30.16 | 2019-2020 | |
| Astellas Pharma US INC | $23.18 | 2020 | |
| Next Science LLC | $18.22 | 2024 | Blastx, Surgx, Xperience |
| Idorsia Pharmaceuticals US INC | $14.93 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Werner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.